AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04835493 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intervention
Description: In the proposed study, we will conduct a randomized clinical trial of low-income, adult Latino(a)s with type 2 diabetes randomized at the individual level a telehealth-supported, integrated CHWs, medication-access, diabetes education program) (intervention) versus usual care (UC). Our research team will provide telementoring to local clinic teams (providers and CHWs) to initiate the 12-month the program into their clinics.
Study NCT06339879 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Whole Grain, Low Sugar
Description: 6 servings of whole grain and \<13% energy from added sugars.
Study NCT05686044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: HPMC (vegetarian source) capsule shells
Study NCT05711082 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Précurseur de la dopamine
Description: In the first condition, volunteers will receive a 100mg dose of L-dopa, 25mg dose of Aromatic amino acid decarboxylase inhibitors (Benserazide) and 10mg dose of Domperidone. In the second condition, volunteers will receive Sulpiride 800mg. In the third condition, volunteers will receive placebo Reality-monitoring performances will be evaluated with a standardized task. Working-memory will be evaluated with the n-back task. Self-monitoring performances will be observed during a speech production experiment in which speakers monitor their auditory feedback while speaking.~Speech Bayesian reasoning: This task is a home-made task investigating the influence of prior on speech processing. Subjects will be required to identify speech in ambiguous auditory stimuli. Visual Bayesian reasoning: This task investigates the influence of prior on visual processing. Subjects will be required to recognize morph between faces and house.
Study NCT05711082 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: antagoniste D2
Description: In the second condition, volunteers will receive Sulpiride 800 mg
Study NCT05711082 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: In the third condition, volunteers will receive placebo
Study NCT05048576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Negative Reinforcement
Description: Terms to be used in negative reinforcement:~You've got to walk faster than that. You're so slow! Why do you walk like that? Did you learn how to walk yesterday? You're doing terrible. Who walks like that? You have potential but you don't use it. You'll never amount to anything. You're not putting very much effort into this. This is the worst pace you've had yet.
Study NCT05048576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Reinforcement
Description: Terms to be used in positive reinforcement:~Good job, you're doing awesome! Keep up the good work! You've got this! You're almost done, just a few more minutes! That's a great pace! You're going strong! Keep it up! Nice work. Great job! Good stuff. Keep it up. You're doing an amazing job.
Study NCT05048576 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Silence
Description: No recordings will be played during this condition.
Study NCT05048576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Participant's can choose their own music to play during this condition.
Study NCT04750616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacinamide
Description: Niacinamide 3 grams on the day of surgery and post-surgical days one and two
Study NCT04750616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo on the day of surgery and post-surgical days one and two
Study NCT05203900 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Infant formula with Human Milk Oligosaccharide
Description: Although breastfeeding is encouraged, the shortage is supplemented with the investigational formula. After obtaining the informed consent, the investigational formula is administered to infants under the doctor's direction until a medical check-up at one-month-old.
Study NCT05203900 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Infant formula without Human Milk Oligosaccharide
Description: Although breastfeeding is encouraged, the shortage is supplemented with the control formula. After obtaining the informed consent, the control formula is administered to infants under the doctor's direction until a medical check-up at one-month-old.
Study NCT05148195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envofolimab
Description: 300mg，Q3W (arm A,B and C)or 200mg, Q2W(arm D)
Study NCT05148195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BD0801
Description: 2mg/kg，Q3W(armA, B and C) or 2mg/kg，Q2W
Study NCT05148195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2，Q3W
Study NCT05148195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m2，Q2W
Study NCT05148195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin calcium
Description: 400mg/m2，Q2W
Study NCT05148195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouridine
Description: 2400 mg/m2，Q2W
Study NCT06125080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone
Description: Utidelone (30 mg/m2, days 1-5, every 3 weeks)
Study NCT06125080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirelizumab
Description: Tirelizumab（200mg, day1, every 3 weeks）
Study NCT06125080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab(7.5mg/kg, day1, every 3 weeks)
Study NCT05155891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embosphere Microspheres
Description: The SOC PAE procedure will be performed by attempting to embolize prostatic arteries of both sides in a single session with 300-500 um Embosphere Microspheres. The microspheres will be mixed with a contrast agent and will be delivered to the arteries supplying the prostate via a microcatheter.
Study NCT05155891 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HoLEP Procedure
Description: The SOC PAE procedure will be performed with the SOC HoLEP as per standard institutional guidelines. The HoLEP procedure involves passing a telescope through the urethra and removing the central part of the prostate gland using a laser.
Study NCT05960721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 15mg
Description: QD
Study NCT05960721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15mg
Description: QD
Study NCT06339879 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Whole Grain, Low Sugar
Description: 3 servings of whole grain and \<13% energy from added sugars.
Study NCT06339879 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Whole Grain, High Sugar
Description: 6 servings of whole grain and >13% energy from added sugars.
Study NCT06339879 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Whole Grain, High Sugar
Description: 3 servings of whole grain and >13% energy from added sugars.
Study NCT05532410 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Fundus Camera
Description: The fundus camera is suitable for photographing, displaying and storing data relating to the retina and surrounding parts of the eye. These photographs assist with the diagnosis and follow-up of eye diseases, which can be visually monitored and photographically documented.
Study NCT06260280 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebral Nuclear Magnetic Resonance
Description: Cerebral Nuclear Magnetic Resonance before the start of the shifts and a control 2 months after the start of the residency to evaluate if there is an association between chronic sleep deprivation and changes in cortical and hippocampal volume.
Study NCT05054725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-4630
Description: RMC-4630 administered orally as a capsule
Study NCT05054725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib administered orally as a tablet
Study NCT05269394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2814
Description: Administered intravenously in a blinded fashion
Study NCT05269394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab
Description: Administered intravenously
Study NCT05269394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lecanemab
Description: Administered intravenously
Study NCT05269394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo (E2814)
Description: Placebo administered intravenously in a blinded fashion.
Study NCT06095765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 MG Oral Tablet
Description: Oral intake of 0.5 mg colchicine once daily
Study NCT06095765 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral intake of matching placebo once daily
Study NCT05960721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 100mg
Description: QD
Study NCT05960721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75mg
Description: QD
Study NCT05960721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10mg
Description: QD
Study NCT05960721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5mg
Description: B.I.D
Study NCT04211675 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Natural Killer Cells
Description: NK cells dose 1x 108 cells/ kg on day 8 of each cycle
Study NCT04211675 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Temozolomide
Description: Temozolomide 100mg/m2/dose PO or IV daily on Days 1-5; if given orally, must be at least one hour prior to Irinotecan. For patients whose body surface area is \<0.5m2, temozolomide dosing is based on body weight in (kg), at a dose of 3.3 mg/kg/dose.
Study NCT04211675 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan
Description: Irinotecan 50mg/m2/dose IV daily on Days 1-5
Study NCT04211675 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dinutuximab
Description: Dinutuximab 17.5mg/m2/dose IV daily on Days 2-5
Study NCT04211675 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sargramostim
Description: Sargramostim 250mcg/m2/dose subcutaneous daily on Days 6-12
Study NCT05194423 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tricuspid Valve Replacement System via jugular vein
Description: To eliminate the tricuspid regurgitation through orthotopically replacing tricuspid valve with LuX-Valve system via jugular vein.
Study NCT06421103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green (ICG)
Description: Cohorts will receive 0.01 mg/kg, 0.02 mg/kg, 0.04mg/kg, 0.06 mg/kg, or 0.08 mg/kg intra-venous ICG at surgery. Patients will be consecutively allocated to different doses as per protocol.
Study NCT05722444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nighttime Feminine Product
Description: During nights while menstruating:~* Standardized nighttime feminine product + typical nighttime behaviors to prevent leak~* Standardized nighttime feminine product + refraining from nighttime behaviors to prevent leak
Study NCT06335745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PediCARE Intervention
Description: A household material hardship intervention with monthly, direct provision of groceries and transportation. Resources will be centrally administered by the Dana-Farber Cancer Institute study team.
Study NCT05867979 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Identify structural variants by Optical Genome Mapping of DNA extracted from blood leukocytes
Description: The one arm of the study will have a venous blood draw as part of the research. 1 EDTA tube of 5mL will be collected.
Study NCT04795336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 5 mg
Description: Melatonin is a widely sold synthetic molecule in various forms including tablets, gummies and liquid. In the present study, the tablet version of the medication will be used at a dose of 5mg
Study NCT04795336 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo ingredients are Microcrystalline Cellulose, Silica, Gelatin, Titanium Dioxide, Red #3, and Blue #1.
Study NCT06471283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activity
Description: Exercising physical activity during dialysis
Study NCT06466018 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Schirmer test paper
Description: This paper is centrifuged and your tears are collected then frozen before analysis. We collect the fat from your tears by scraping the edge of your lower eyelid with small sterile tweezers. All surgical waste will be collected during eye surgeries only if you must have them.~During each ocular surgical procedure, the vitreous, subretinal fluids and/or aqueous humor will eventually be recovered when required by the procedure. The rest of the blood samples, not used during diagnostic analyses, will be kept for later analyses.~Tears will be collected using a non-invasive and painless method that takes around ten minutes. The tissues (connectiva, cornea, retina, epi-retinal membrane) which must have been removed when required by the surgical procedure will also be preserved.
Study NCT06303609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nonablative radiofrequency
Description: The active electrode from the nonablative radiofrequency will be applied to the urogenital- and uroanal trigone and the dispersive electrode will be attached to the back of the patient. The water-soluble gel will be applied to the active electrode and to the non-lubricated condom which will involve the electrode. There will be a gradual increase in temperature, monitored by a digital infrared thermometer, to reach temperature between 36°C and 38°C, keeping the movement for two minutes in each area, spending in total around 10 minutes.
Study NCT06303609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal dilator
Description: Both groups will use the vaginal dilator at the end of each session for 15 minutes and all patients will be advised to use it for 15 minutes daily in a home based treatment.
Study NCT06303609 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal dilator
Description: Both groups will use the vaginal dilator at the end of each session for 15 minutes and all patients will be advised to use it for 15 minutes daily in a home based treatment.
Study NCT06303609 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham nonablative radiofrequency
Description: The active electrode from the nonablative radiofrequency will be applied to the urogenital- and uroanal trigone and the dispersive electrode will be attached to the back of the patient. The water-soluble gel will be applied to the active electrode and to the non-lubricated condom which will involve the active electrode. As the device will not deliver the radiofrequency wave, the gel will be heated so the patient has the feeling of the temperature change, keeping the movement for two minutes in each area, spending in total around 10 minutes.
Study NCT04991298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral premedication
Description: Oral anesthesia premedication for congenital Cardiac surgery
Study NCT05090293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Lifestyle Intervention with Body Image Treatment (LIBI)
Description: A body image protocol designed to improve outcomes in a group-delivered multidisciplinary weight loss program by addressing body acceptance within a context of positive behavior change and utilizing existing body discomfort and re-purposing it as an agent of motivation.
Study NCT05090293 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Intervention (LI)
Description: A multidisciplinary, group-delivered, multidisciplinary weight loss program addressing various lifestyle factors impacting weight loss.
Study NCT01207622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Study NCT01207622 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT06466018 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Schirmer test paper
Description: This paper is centrifuged and your tears are collected then frozen before analysis. We collect the fat from your tears by scraping the edge of your lower eyelid with small sterile tweezers. All surgical waste will be collected during eye surgeries only if you must have them.~During each ocular surgical procedure, the vitreous, subretinal fluids and/or aqueous humor will eventually be recovered when required by the procedure. The rest of the blood samples, not used during diagnostic analyses, will be kept for later analyses.~Tears will be collected using a non-invasive and painless method that takes around ten minutes. The tissues (connectiva, cornea, retina, epi-retinal membrane) which must have been removed when required by the surgical procedure will also be preserved.
Study NCT04988360 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HMD: Immersive VR
Description: Participants with dementia will view 360-degree films using a commercially-available Virtual Reality head mounted display (HMD) that has built-in speakers. While wearing the HMD, participants with dementia will be able to visually explore the virtual environments by turning their head to face different directions. Caregivers-participants will take part in the VR experience concurrently by viewing a tablet that is connected to the HMD through the screen mirroring function.
Study NCT04988360 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tablet: Non-immersive VR
Description: Participants with dementia will view 360-degree films on a commercially-available tablet that has built-in speakers. Participants with dementia will be able to visually explore the virtual environment using the touch screen (dragging the view around with one's finger). Caregiver-participants will take part in the VR experience concurrently by viewing the tablet while sitting or standing beside the participant with dementia.
Study NCT04331743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-entrapped Mitoxantrone Hydrochloride Injection
Description: Intravenous infusion
Study NCT04797624 — intervention group
Intervention type: PROCEDURE
Intervention: Gastric cancer surgery
Description: Appropriate gastric cancer surgery types for the convenient patients
Study NCT06455046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: PD-1/CTLA-4 bispecific antibody
Study NCT06455046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Adenovirus 5 Injection
Description: Recombinant Human Adenovirus 5 Injection
Study NCT06141356 — intervention group
Intervention type: DRUG
Intervention: [18F]Florbetazine ([18F]92)
Description: Participants will receive a single intravenous bolus injection of 10 mCi ± 20% of the investigational radiotracer \[18F\]Florbetazine and will undergo a PET/CT scan.
Study NCT06141356 — intervention group
Intervention type: DRUG
Intervention: [11C]PIB
Description: Participants will receive a single intravenous bolus injection of 6.0-20.0mCi of the investigational radiotracer \[11C\]PIB and will undergo a PET/CT scan.
Study NCT05331859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Topical insulin drops will be prepared by diluting 1 unit of rapid-acting insulin per 1 mL of an artificial tear with a propylene glycol base. Drops will be preserved at low temperature (2ºC) and applied four times a day.
Study NCT05331859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: autologous serum (AS)
Description: Whole blood (20 ml) wll be procured by venipuncture, centrifuged at 1,500 revolutions per minute (relative centrifugal force of 25.15 × g) for 10 minutes. AS drops will be carefully prepared under a laminar airflow cabinet, and diluted with artificial tears (Systane ultra; Alcon) to 20%. AS drops will be prepared on the day of surgery and patients will be asked to keep AS drops refrigerated at about 4C.
Study NCT05331859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional
Description: Topical moxifloxacin 0.5% (Vigamox; Alcon Laboratories) four times per day, artificial tears (Systane ultra; Alcon) every two hours, Dexamethasone 0.1% (Maxidex; Alcon Laboratories) four times daily for one month then fluorometholone 0.1% (Efemyo; Orchidia Laboratories) four times daily for another two to four weeks depending on refraction and haze level.
Study NCT05331859 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: conventional
Description: Topical moxifloxacin 0.5% (Vigamox; Alcon Laboratories) four times per day, artificial tears (Systane ultra; Alcon) every two hours, Dexamethasone 0.1% (Maxidex; Alcon Laboratories) four times daily for one month then fluorometholone 0.1% (Efemyo; Orchidia Laboratories) four times daily for another two to four weeks depending on refraction and haze level.
Study NCT05366400 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ECHO
Description: Conventional routine tests and ECHO will be assessed. Biomarkers will be measured using ELISA The functional capacity was assessed by the COPD assessment test (CAT) questionnaire.
Study NCT05173116 — intervention group
Intervention type: OTHER
Intervention: Medical Outcomes Study Short Form 36 (SF 36)
Description: completion of questionnaire quality of life SF 36 (inclusion, Month 3, Month 6).
Study NCT05173116 — intervention group
Intervention type: OTHER
Intervention: observationnal study
Description: data collection